Nektar Therapeutics reported $-158968000 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Biogen BIIB:US $ 874.8M 28.6M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Cara Therapeutics CARA:US $ -4206000 23.54M
Dr.Reddys Laboratories DRRD:IN IR 14680M 4672M
Eisai 4523:JP Y 9722M 30501M
Esperion Therapeutics ESPR:US $ -66324000 9.59M
Exelixis EXEL:US $ 88.51M 3.28M
Halozyme Therapeutics HALO:US $ 30.01M 51.62M
Immunogen IMGN:US $ -62.02M 37.88M
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Macrogenics MGNX:US $ -41.3M 25.14M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Nektar Therapeutics NKTR:US $ -158.97M 68.7M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Novartis NOVN:VX SF 4129M 217M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Takeda 4502:JP Y 155473M 209520M
Teva Pharmaceutical TEVA:IT -1160000000 189M
Xencor XNCR:US $ -33.98M 57.57M